

# Press Release: JNHB Updates Process Guideline and Dossier Template after involvement of Nordic Pharmaceutical Associations

In 2024, JNHB introduced a process guideline and a dossier submission template to provide guidance to Health Technology Developers (HTDs) engaging with JNHB.

At JNHB, we are committed to lay out robust and efficient processes, and we continuously work to develop them. To better understand the concerns of HTDs and improve our guidance, we have engaged in productive dialogues with pharmaceutical industry associations across the Nordic countries.

## Key Updates in the Process Guideline:

- The terminology has been adjusted to distinguish it from process steps described in the EU HTA-regulation.
- The assessment period is defined as 90 working days.
- The observer role has been clarified.

## Changes in the Dossier Template:

The modifications are mostly minor and focus on wording adjustments to emphasize that the template is supportive rather than mandatory. By outlining the preferred input, the template aims to facilitate the submission process and ensure a smoother assessment.

We believe that these updates, developed in dialogue with industry associations, will enhance the transparency and efficiency of our processes. We remain open for communication and cooperation with all stakeholders to achieve our shared goals.